secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2026-02-04T23:59:59+00:00
Accession:  0001087294-26-000011
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharma gets FDA Fast Track for ifetroban in DMD heart disease
------------------------------------------------------------------------

- FDA Fast Track Designation granted for ifetroban targeting fatal heart disease in Duchenne muscular dystrophy.
- Designation follows previous Orphan Drug and Rare Pediatric Disease Designations for same indication.
- Phase 2 FIGHT DMD trial showed 5.4% improvement in left ventricular ejection fraction over 12 months.
- Fast Track enables expedited review, rolling submission, and more frequent FDA interactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000108729426000011/0001087294-26-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000108729426000011/cpix-20260204.htm
  HTML page:      https://secwatch.observer/filing/0001087294-26-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer